91探花

As GLP-1 usage grows, so does the demand for wraparound care. The recent funding of $100 million for Nourish and $20 million for Signos in May 2026 proves that the real opportunity isn鈥檛 just in the medication 鈥� it鈥檚 in the digital coaching, nutrition and metabolic monitoring that helps patients make their weight loss results stick.

The clinical rationale behind this market is well-founded. GLP-1 therapy is now often paired with resistance training, protein targets and micronutrient monitoring to help preserve lean mass, and at least one study has found that patients combining GLP-1 medication with nutrition therapy lost less muscle mass than those on medication alone. Morgan Stanley has projected that the GLP-1 category could roughly double to $190 billion by 2035, which explains why investors and incumbents are moving quickly to build the layer of care around the medication itself.

Moving quickly doesn鈥檛 mean every part of that layer has equal clinical value. We asked the people prescribing these medications, building the platforms and advising patients directly to separate what actually helps from what鈥檚 riding the wave.

听

Identifying the Core Clinical Value

听

A clear pattern emerges across the responses: nutrition counselling, dietary guidance around protein and micronutrients, resistance training support and side-effect management have the strongest evidence base of any part of the emerging GLP-1 care stack. These are the elements that show up repeatedly in clinical guidance and that clinicians describe as making a measurable difference to whether patients maintain muscle mass and sustain results once treatment stabilises or stops.

AI meal-tracking and scoring tools occupy more contested territory. Several contributors describe them as helpful for adherence and self-awareness, while being honest that the underlying health technology still struggles with the basics: identifying mixed meals, hidden cooking oils and accurate portion sizes from a photograph. The tools appear to work best as a layer that supports a clinical relationship rather than as a substitute for one 鈥� a distinction that matters more in this category than the funding headlines tend to suggest.

What separates the models likely to last from the ones that won鈥檛 is whether they鈥檙e built around active clinical oversight or designed as standalone consumer products. The strongest indicators point toward models with active clinical oversight built in from the outset, rather than nutrition or tracking tools sold as an add-on to a prescription that already exists.

听

Our Experts

听

听

• Hira Malik, Superintendent Pharmacist and Co-Founder, Oushk Pharmacy
• Joseph Zucchi, PA-C, MPAS, Clinical Supervisor, Transition Medical Weight Loss
• Dr. Daniel Careaga, Founder, Careaga Plastic Surgery
• Evan Nadler MD, MBA, Adjunct Associate Professor of Surgery and Pediatrics, George Washington University
• Dave Dowman, COO, My Local Surgery

听

听

Hira Malik, Superintendent Pharmacist and Co-Founder, Oushk Pharmacy

鈥淭he most valuable part of the care ecosystem around GLP-1 medication is whether it improves clinical oversight and patient behaviour between reviews.

鈥淣utrition support, protein and fibre guidance, hydration advice, side-effect management and resistance training education all have clear practical value because they help patients maintain muscle mass, tolerate treatment and build habits that last beyond the prescription. Digital tools can support this, but they should not replace pharmacist or clinician-led monitoring.

鈥淭he most commercially viable models will integrate support into care rather than bolt it on as a lifestyle extra. Patients need eligibility checks, dose reviews, safety monitoring, nutrition guidance and a clear long-term plan for maintenance or stopping treatment.

鈥淭he growth of this market shows a real gap in healthcare. Medicines can be effective, but outcomes depend on the support around them. The opportunity is to build digital care that is clinically accountable.鈥�

听

Joseph Zucchi, PA-C, MPAS, Clinical Supervisor, Transition Medical Weight Loss

听

鈥淕LP-1 medications are fantastic tools, but the patients who tend to do best are not simply handed a prescription and left on their own. They do best when medication is paired with practical nutrition guidance, exercise support, accountability and easy access to a care team when questions come up.

鈥淚n my practice, we use tools that give patients a simple way to journal food if they choose, track exercise and sleep, message us about side effects or refills, and attend virtual or in-person visits. Telehealth platforms have also made it much easier to meet patients where they are, especially when work, travel, childcare or distance would otherwise get in the way of follow-up care.

鈥淭hese tools can help fill the gaps between visits, but they should make care simpler, not more overwhelming. AI meal-tracking tools are promising, although they still have limitations. They can estimate what is visible in a photo, but mixed meals, ingredients, cooking oils and portion sizes remain difficult to assess accurately.

鈥淭he real value is not another app telling someone to eat less. It is helping patients protect muscle, prioritise protein, manage side effects, stay active and build habits that last. Technology works best when it supports the relationship between the patient and their care team, rather than trying to replace it.鈥�

听

Dr. Daniel Careaga, Founder, Careaga Plastic Surgery

听

鈥淎s a prescribing physician, the best support I see is care that assists patients in establishing behaviours they can use beyond the prescription. Nutrition counselling, advice on sufficient protein intake, strength training to help maintain lean muscle mass, regular follow-up and patient education are all of clinical value because they enhance both weight loss and long-term maintenance of weight loss.

鈥淭he services most likely to be commercially viable are those that stay closely linked with active medical care, evolving alongside treatments as they meet patients鈥� needs. They require something more than medication or another short-term solution. Patients do best when their progress is routinely physician-reassessed, their treatment plan is modified as needed, and they are provided with hands-on guidance on how to integrate lifestyle changes into their existing routine.

鈥淭he growth of this market signals an important gap: prescribing a medication should be combined with ongoing medical support for patients on their journey to losing weight. The value of many digital health tools lies in their ability to reinforce physician-directed care and help patients remain engaged, as opposed to acting as a substitute for individualised medical care.鈥�

听

Evan Nadler MD, MBA, Adjunct Associate Professor of Surgery and Pediatrics, George Washington University

听

鈥淭he supply chain shortages and the advent of compounding pharmacies producing online options allowed the market to get ahead of itself. Many people started taking GLP-1 knock-offs without great medical supervision and are now taking brand name drugs but still without the proper wraparound support. What the data show is that behavioural support to achieve lifestyle changes, including a healthier diet and a proper exercise component, results in greater weight loss and medical benefit than the medications alone.

鈥淗owever, what that exactly requires and how to make it happen is still up for debate. Programmes with as little as an hour a month of contact time can perform as well as those with 26 hours over six months. And data from bariatric surgery, which has been around for 35 years, shows that the hype over muscle loss is not relevant for most patients, although resistance training, especially upper body resistance training, is recommended for all patients undergoing a weight loss intervention.

鈥淭he real gap is clinical trial-level evidence that shows which digital health initiatives provide value versus which are merely money grabs. I鈥檓 obviously biased, but I think having access to a medical provider in addition to any AI-generated advice will be crucial to the medical success of any digital health intervention 鈥� though providers are more expensive than AI-generated guidance alone. Those AI-only solutions may be more commercially viable in the short term, but will likely prove insufficient in the long term.鈥�

听

Dave Dowman, COO, My Local Surgery

听

鈥淕LP-1 medications were never intended to be used in isolation, and the side effects of misusing them, particularly inadequate nutrition and strength training alongside treatment, are driving a coinciding movement of nutrition counselling, muscle preservation and habit support. GLP-1s are intended to be used gradually to manage diabetes, obesity and reduce the risk of cardiovascular events, and a healthy lifestyle alongside the medication is crucial for using it safely. There鈥檚 a risk that companies are monetising every aspect of the patient journey without evidence behind it.

鈥淭he ecosystem emerging across nutrition, muscle preservation and habit stacking is a nuanced subject. Many GLP-1 users need additional nutritional and exercise support, so medically-approved, robust support can be immensely helpful. However, the lines are blurred between what鈥檚 genuinely medically-backed and what鈥檚 opportunistic, so it鈥檚 crucial that tools are verified by accredited medical professionals.

鈥淪tructured nutritional support from medical professionals can help patients maintain muscle and hit protein and micronutrient goals alongside strength training, but this advice needs to come from a verified healthcare professional. Companies offering nutritional 鈥榚ducation鈥� without verified experts risk misinforming patients. For monitoring weight loss and dose escalation, pharmacists, GPs or dietitians are the only people who should be advising. Apps can assist with habit building, but they cannot substitute real medical advice.

鈥淪ustained care looks like treating GLP-1s as one component of obesity management rather than a solution on their own, with a clear treatment plan and medical support at every step. The growth of this market reveals a real gap between pharmaceutical prescribing and the long-term support needed to make that prescribing safe and successful. Digital health tools have a role to play, but they need regulation to ensure they鈥檙e not offering misinformation, and should assist rather than replace evidence-based, clinically supervised care from real healthcare professionals.鈥�